Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of BSRBR-RA Registry data.

Christopher J Edwards,Julie Mount,Alexandra Meeks,Tania Gulati,Liliana Zaremba-Pechmann, Mohamed Sheesh,Esbjörn Larsson,Elaine Dennison

Rheumatology (Oxford, England)（2023）

引用 1|浏览18

暂无评分

摘要

In the early years of real-world baricitinib use in the UK, a high proportion of patients continued with treatment at both 6 and 12 months, at which times disease activity was lower than at baseline.

查看译文

关键词

Baricitinib,Janus kinase inhibitor,observational study,real-world,registry,rheumatoid arthritis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要